Schizophrenia Clinical Trials in Boston, Massachusetts

13 recruitingBoston, Massachusetts

Showing 113 of 13 trials

Recruiting

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Schizophrenia
Bristol-Myers Squibb300 enrolled18 locationsNCT07101094
Recruiting
Phase 3

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences560 enrolled17 locationsNCT07227818
Recruiting
Phase 3

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

Schizophrenia
Bristol-Myers Squibb166 enrolled44 locationsNCT07288567
Recruiting
Phase 3

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

SchizophreniaAutism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company400 enrolled55 locationsNCT07424404
Recruiting
Not Applicable

Cerebellar Modulation of Cognition in Psychosis

SchizophreniaPsychosisSchizoaffective Disorder+1 more
Mclean Hospital95 enrolled2 locationsNCT06107764
Recruiting
Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

SchizophreniaSchizoaffective DisorderDelusional Disorder+4 more
Beth Israel Deaconess Medical Center320 enrolled6 locationsNCT06740383
Recruiting
Not Applicable

Enhanced Coordinated Specialty Care for Early Psychosis

SchizophreniaBipolar DisorderPsychosis+2 more
Mclean Hospital350 enrolled5 locationsNCT06071858
Recruiting
Phase 2

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Depression, AnxietySchizophreniaPsychiatric Disorder+5 more
Brigham and Women's Hospital180 enrolled2 locationsNCT06376734
Recruiting
Phase 4

CLOZAPINE Response in Biotype-1

SchizophreniaSchizoaffective DisorderBipolar 1 Disorder
University of Texas Southwestern Medical Center524 enrolled5 locationsNCT04580134
Recruiting
Not Applicable

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

Traumatic Brain InjurySchizophreniaSubstance Use Disorders+4 more
Massachusetts General Hospital600 enrolled1 locationNCT04296604
Recruiting
Phase 3

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335